125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
NCT07277777
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Malignant Tumors
Interventions
DRUG:
Immune Checkpoint Inhibitors
OTHER:
125I Seed Implantation
DRUG:
Immune Checkpoint Inhibitors
Sponsor
Li Min